RSSDI releases guidelines for management of Hypertension in Diabetes Mellitus 2022
Written By : Dr. Nandita Mohan
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2022-12-23 06:45 GMT | Update On 2023-10-11 09:25 GMT
Advertisement
Catering to the pressing need to outline an evidence and experience-based comprehensive treatment yardstick, the first-ever Indian guideline for the management of hypertension in Diabetes Mellitus has been released by the RSSDI on the 15th of Dec 2022.
The guideline has been published in the latest issue of the International Journal of Diabetes in Developing Countries – the IJDDC.
The guideline recommends that :-
- Calcium channel blockers (CCBs) must be preferred over beta-blockers and thiazides in combination therapy with Angiotensin II Receptor blockers (ARBs) for better cardiovascular and renoprotection in diabetic hypertensive Indian patients.
- Cilnidipine to be a comparatively more effective and safer novel molecule as compared to conventional CCBs for Indian diabetic hypertensive patients (Grade A recommendation).
- ARBs must be preferred over ACEi in diabetic patients with hypertension, telmisartan or azilsartan being selected as the first-line agent (grade B recommendation).
- ARBs, either alone or in combination with CCBs, can be used for blood pressure (BP) control in diabetic patients.
- Among the CCBs, novel molecules (e.g.cilnidipine) are recommended in combination with ARBs for better cardiovascular and reno-protection in diabetic hypertensive patients.
- Cilnidipine is a comparatively more efective and safer novel molecule as compared to conventional CCBs for Indian diabetic hypertensive patients (grade A recommendation).
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.